Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities : a multicenter retrospective study using three propensity score analyses
Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion transporters. Thus, this study aimed to clarify whether RAS inhibitors (RASIs) could prevent pemetrexed plus platinum-induced hematological toxicities. We retrospectively analyzed data from 305 consecutive patients with non-small cell lung cancer or malignant pleural mesothelioma who received their first cycle of a pemetrexed plus platinum regimen and were treated with or without RASIs. The primary endpoint was the incidence of severe myelosuppression after the first cycle. Propensity score (PS)-matched, PS-adjusted, and inverse probability of treatment weighting (IPTW) analyses were used. The number of patients with grade ≥3 hematological toxicities was 27 (8.9%). PS-matched analyses revealed that the concomitant use of RASIs was slightly associated with a lower risk of grade ≥3 hematological toxicities (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.20-2.32; p = 0.536). Additionally, sensitivity analyses using PS-adjusted and IPTW methods demonstrated similar results (OR, 0.63; 95% CI, 0.19-2.15; p = 0.463 and OR, 0.37; 95% CI, 0.11-1.29; p = 0.117, respectively). These findings suggest that RASIs might prevent pemetrexed plus platinum-induced hematological toxicities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Die Pharmazie - 76(2021), 6 vom: 01. Juni, Seite 266-271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arami, T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04Q9AIZ7NO |
|---|
| Anmerkungen: |
Date Completed 31.01.2022 Date Revised 31.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1691/ph.2021.1409 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326269320 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326269320 | ||
| 003 | DE-627 | ||
| 005 | 20231225194229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1691/ph.2021.1409 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326269320 | ||
| 035 | |a (NLM)34078521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arami, T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities |b a multicenter retrospective study using three propensity score analyses |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2022 | ||
| 500 | |a Date Revised 31.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion transporters. Thus, this study aimed to clarify whether RAS inhibitors (RASIs) could prevent pemetrexed plus platinum-induced hematological toxicities. We retrospectively analyzed data from 305 consecutive patients with non-small cell lung cancer or malignant pleural mesothelioma who received their first cycle of a pemetrexed plus platinum regimen and were treated with or without RASIs. The primary endpoint was the incidence of severe myelosuppression after the first cycle. Propensity score (PS)-matched, PS-adjusted, and inverse probability of treatment weighting (IPTW) analyses were used. The number of patients with grade ≥3 hematological toxicities was 27 (8.9%). PS-matched analyses revealed that the concomitant use of RASIs was slightly associated with a lower risk of grade ≥3 hematological toxicities (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.20-2.32; p = 0.536). Additionally, sensitivity analyses using PS-adjusted and IPTW methods demonstrated similar results (OR, 0.63; 95% CI, 0.19-2.15; p = 0.463 and OR, 0.37; 95% CI, 0.11-1.29; p = 0.117, respectively). These findings suggest that RASIs might prevent pemetrexed plus platinum-induced hematological toxicities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Pemetrexed |2 NLM | |
| 650 | 7 | |a 04Q9AIZ7NO |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 700 | 1 | |a Kawazoe, H |e verfasserin |4 aut | |
| 700 | 1 | |a Uozumi, R |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, H |e verfasserin |4 aut | |
| 700 | 1 | |a Egami, S |e verfasserin |4 aut | |
| 700 | 1 | |a Sakiyama, N |e verfasserin |4 aut | |
| 700 | 1 | |a Ohe, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Nakada, H |e verfasserin |4 aut | |
| 700 | 1 | |a Aomori, T |e verfasserin |4 aut | |
| 700 | 1 | |a Ikemura, S |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, H |e verfasserin |4 aut | |
| 700 | 1 | |a Kawada, I |e verfasserin |4 aut | |
| 700 | 1 | |a Fukunaga, K |e verfasserin |4 aut | |
| 700 | 1 | |a Soejima, K |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Die Pharmazie |d 1947 |g 76(2021), 6 vom: 01. Juni, Seite 266-271 |w (DE-627)NLM000009180 |x 0031-7144 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2021 |g number:6 |g day:01 |g month:06 |g pages:266-271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1691/ph.2021.1409 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2021 |e 6 |b 01 |c 06 |h 266-271 | ||